Evidence map›Paper›PMID 42169560›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2026

Functional analysis of a splicing variant of the DOCK8 gene in a patient with breast cancer (Buryat ethnicity).

Polina Gervas, Ramil Salakhov, Aleksey Molokov, Yuliya Karpova, Natalya Babyshkina, Michail Buldakov, Matvei Tsyganov, Lilya Molonova, Alexey Zarubin, Lianhui Wang and 2 more

Abstract readCase Reports
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Polina GervasDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0003-0051-8814
Ramil SalakhovDepartment of genomic medicine, Endocrinology Research Centre, Moscow, Russia.
Aleksey MolokovDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.
Yuliya KarpovaDepartment of genomic medicine, Endocrinology Research Centre, Moscow, Russia.
Natalya BabyshkinaDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0002-0562-3878
Michail BuldakovDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.
Matvei TsyganovDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0001-7419-4512
Lilya MolonovaDepartment of Surgery, Buratya Republic Cancer Center, Ulan -Ude, Russia.
Alexey ZarubinDepartment of population genetics, Research Institute of Medical Genetics, Tomsk National Research Medical Center, Tomsk, Russian Federation.
Lianhui WangInstitute of Advanced Materials, Nanjing University of Posts and Telecommunications, Nanjing, China.
Eugene ChoynzonovDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.
Nadezda CherdyntsevaDepartment of Cancer Research, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0003-1526-9013

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRCA1/2 founder mutation have been detected in various populations and ethnicities. Molecular diagnosis of HBOC remains challenging for populations where founder mutations have not yet been identified. There are limited data on hereditary BC mutations in ethnic groups of Siberia. The purpose of this study was to find new hereditary breast cancer (BC) variants in the understudied Buryat ethnic group by using WES data and DNA construct for their subsequent validation.<br /><br />Methods: Our study included a 52-year-old Buryat BC patient with a family history of BC (sister with BC). To identify novel as well as previously described variants, obtained by WES, we used the OpenCRAVAT mutation impact scoring algorithm (comprehensive knowledge base). For variants requiring further study, the DNA construct method was used. <br /><br />Result: According to WES data, no pathogenic variants were found in a 52-year-old Buryat BC patient with a family history of BC. The patient was found to have rare variants of unknown significance (MLH1 c.C550T:p.R184C and FANCI c.A1111G:p.S371G) and c.986C>T DOCK8 gene variant (as secondary findings). In silico analysis indicated that only c.986C>T variant of DOCK8 gene may affect splicing (a key immunity gene could act as a tumor suppressor). Electrophoresis of PCR fragments obtained using cDNA as a template showed that in the presence of the c.986C>T variant, the length of the PCR product was 60 bp less than in the case of the reference sequence of this region. <br /><br />Conclusion: We suggest that the combined carriage of the c.A1111G mutation of the FANCI gene and c.986C>T DOCK8 gene identified in this patient may likely increase the risk of developing BC. Our functional data indicate a potential impact c.986C>T variant of the DOCK8 gene on splicing. The role of the c.986C>T variant in BC pathogenesis and its prevalence in Buryats ethnic group remain to be elucidated.

Indexed as

Biomarkers, TumorBreast NeoplasmsGenetic Predisposition to DiseaseGuanine Nucleotide Exchange FactorsMutationRNA SplicingFemaleHumansMiddle AgedPrognosisBiomarkers, TumorDOCK8 protein, humanGuanine Nucleotide Exchange Factorsbreast cancerBuryatDNA constructDOCK8

Identifiers

PMID42169560
PMCPMC13650041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.